FDA Approves Alembic's Generic Venetoclax Tablets
The generic version of AbbVie's Venclexta is rated therapeutically equivalent, though launch timing and price remain unannounced.
Updated on Nov. 6, 2026 in Cancer
Live Poll
Do you think generic drugs are making prescription prices affordable for you?
The FDA granted final approval to a generic version of venetoclax made by India-based Alembic Pharmaceuticals, which Alembic announced on October 30, 2026. The tablets are rated therapeutically equivalent to AbbVie's Venclexta, but Alembic has not said when the drug will reach pharmacies or what it will cost.
Why it matters
Venclexta's orphan drug exclusivity ended in May 2026, clearing one regulatory barrier to generic competition for this cancer treatment. Generics typically lower prices, though actual savings for patients depend on launch timing, competition, and insurance coverage.
The FDA approval covers 10-milligram, 50-milligram, and 100-milligram tablets rated therapeutically equivalent to Venclexta, whose list price is about $16,089 for a 30-day supply at 400 milligrams daily. Drugs.com still shows patents tied to venetoclax extending into 2033, and the commercial launch timing for the generic has not been disclosed.
The players
Alembic Pharmaceuticals
An India-based drugmaker that filed to challenge Venclexta's patents and received FDA approval for its generic venetoclax tablets.
Dr. Reddy's Laboratories
An Indian pharmaceutical company that received approval for its own generic venetoclax in May 2026 and was also a first filer against Venclexta's patents.
AbbVie
The drugmaker that markets Venclexta, the brand-name venetoclax tablet that the generic is rated therapeutically equivalent to.
U.S. Food and Drug Administration
The federal agency that granted final approval to the Alembic generic and oversees generic drug equivalence ratings.
The details
The generic tablets must contain the same active ingredient, strength, and dosage form as the brand. Venetoclax works by blocking BCL-2, a protein that helps cancer cells avoid normal cell death. Dr. Reddy's Laboratories received approval for its own generic in May 2026, but Drugs.com lists that version as not yet commercially available.
Timeline
2016: Venetoclax was first approved by the FDA.
May 2026: Dr. Reddy's generic venetoclax was approved.
May 15, 2026: Venclexta's orphan drug exclusivity ended.
October 30, 2026: Alembic announced FDA approval of its generic.
2033: Venetoclax-related patents extend into this year.
Health Landscape
The approval follows the expiration of Venclexta's orphan drug exclusivity on May 15, 2026, which opened the path for multiple generic applications under the Orphan Drug Act framework. It marks a shift for a cancer therapy first approved in 2016 whose high list price has drawn scrutiny for leukemia patients.
Patients on venetoclax may eventually pay less once generics reach pharmacies, but the launch date and price are not yet set. Anyone taking the drug should check with their pharmacy and insurer about coverage before switching.
The takeaway
Generic approval is a step toward lower costs, but timing matters: a cleared FDA approval does not mean a generic is on pharmacy shelves yet. Patients should confirm availability and pricing with their pharmacist before expecting savings.
What happens next
Alembic and Dr. Reddy's may each be eligible for 180 days of generic exclusivity, which would shape when additional competitors can enter the market.
Further reading
For related coverage, explore more Cancer news and analysis.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you think generic drugs are making prescription prices affordable for you?
